Tacrolimus is a widely used macrolide immunosuppressant that has a narrow therapeutic index and potential side effects including neurotoxicity. A 20-month-old boy with kidney disease secondary to prune belly syndrome variant, managed on peritoneal dialysis, received a deceased donor transplant. Standard immunosuppression was used. There was good early graft function. Post-transplant he developed fungal peritonitis associated with a significant reduction in graft function and was treated with caspofungin and fluconazole. Despite tacrolimus dose reduction he developed a rapid rise in tacrolimus concentration to a maximum of 72 ng/ml with an otherwise unexplained reduction in consciousness. He underwent a single volume exchange transfusion with packed red cells and 4.5% albumin (ratio 2:1). This resulted in immediate reduction of his tacrolimus concentration from 61.8 ng/ml to 35.2 ng/ml. The neurological deficit rapidly resolved. The fungal peritonitis was eradicated. Renal function recovered from a nadir of eGFR <10 ml/min/1.73 m² to a baseline of 30 ml/min/1.73 m². At 30 months post-transplant the child has creatinine of 1.4 mg/dl (eGFR of 31 ml/min/1.73 m²), and is developmentally appropriate with no neurological deficit. Red cell exchange transfusion is a potentially safe and effective way of managing severe and symptomatic tacrolimus toxicity.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00467-011-1985-8 | DOI Listing |
FASEB J
January 2025
Department of Blood Transfusion, Xiangya Hospital, Central South University, Changsha, China.
Hemolytic anemia (HA) is characterized by massive destruction of red blood cells (RBCs) and insufficient oxygen supply, which can lead to shock, organ failure, even death. Recent studies have preliminarily demonstrated the therapeutic effectiveness of whole blood exchange (WBE) in the management of acute hemolytic anemia and exhibited potential for reducing the duration of corticosteroid treatment, while the underlying mechanism of WBE therapy was not investigated in preclinical study. Hence, we investigate the therapeutic mechanisms of WBE in HA through established continued WBE therapy in rats creatively.
View Article and Find Full Text PDFTransfusion
January 2025
Hematology-Oncology and Cell Therapy University Institute, Hôpital Maisonneuve-Rosemont Research Center, Montréal, Quebec, Canada.
Background: Cold agglutinin disease (CAD) or syndrome (CAS) can be particularly challenging when autologous stem cell transplant (ASCT) is needed. Standard peripheral blood stem cell (PBSC) collection and manipulation involve ex vivo blood manipulations at lower than body temperature, predisposing to agglutination during graft collection, handling, processing, and infusion.
Study Design And Methods: We describe the first case of ASCT for relapsing lymphoma in a patient with high-titer CAD requiring anti-complement therapy and chronic transfusion.
Background: Babesiosis poses significant risks of adverse outcomes in individuals with immunocompromising conditions (IC) and asplenia/hyposplenia (AH). This study compares clinical outcomes between these vulnerable groups and immunocompetent patients.
Methods: A multicenter retrospective cohort study included adult patients with laboratory-confirmed babesiosis from 2009 to 2023.
BMJ Glob Health
January 2025
Sickle Cell Programme, Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Despite progress in healthcare services for individuals living with sickle cell disease (SCD) in Africa, substantial gaps remain in advanced treatments for SCD. To help address this burden, Tanzania has established one of the largest single-centre SCD programmes in the world and developed an advanced therapy programme for SCD focused on patient engagement and advocacy, clinical activities involving exchange blood transfusion (ExBT) and haematopoietic stem cell transplant (HSCT), gene therapy (GT) preparedness, and enabling partnerships. This report describes the programme's genesis, structure and progress achieved.
View Article and Find Full Text PDFHeliyon
January 2025
Cooperative Major in Advanced Biomedical Sciences of Tokyo Women's Medical University and Waseda University, 2-2, TWIns, Wakamatsu-cho, Shinjuku-ku, Tokyo, 162-8480, Japan.
Due to the spread of SARS-CoV-2 virus infectious disease (COVID-19), blood donation events had to be cancelled, and there were concerns about a decrease in the number of blood donors from late February 2020 in Japan. The purpose of this study is to investigate the numbers of whole blood donation, manufacture and inventory adjustment of red blood cell (RBC) products at the Japanese Red Cross Society (JRCS), and to evaluate the effects of COVID-19 on the donation of blood and the supply of RBC products to medical institutions for transfusion medicine in Japan. We focused on RBC products, which are the most frequently used blood products and are easily reflected under the spread of COVID-19.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!